Crotedumab

Crotedumab (REGN1193) is a fully human IgG4 monoclonal antibody that binds and inhibits glucagon receptor (GCGR), with a KD of 0.1 nM. Crotedumab can be used for the research of diabetes[1][2].

Product Specifications

CAS Number

[1452387-69-7]

Product Name Alternative

REGN1193; Anti-GCGR Reference Antibody (crotedumab)

UNSPSC

12352203

Target

GCGR

Type

Inhibitory Antibodies

Related Pathways

GPCR/G Protein

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/crotedumab.html

Purity

99.94

Solubility

H2O

Smiles

[Crotedumab]

Molecular Weight

(146.82 kDa)

References & Citations

[1]Kostic A, et, al. A first-in-human pharmacodynamic and pharmacokinetic study of a fully human anti-glucagon receptor monoclonal antibody in normal healthy volunteers. Diabetes Obes Metab. 2018 Feb;20 (2) :283-291. |[2]Okamot H, et, al. Glucagon Receptor Blockade With a Human Antibody Normalizes Blood Glucose in Diabetic Mice and Monkeys. Endocrinology. 2015 Aug;156 (8) :2781-94.